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Abstract: Herein, we report an environmentally friendly, rapid, and convenient one-pot ultrasound-
promoted synthesis of 5-amino-2-(4-chlorophenyl)-7-substituted phenyl-8,8a-dihydro-7H-(1,3,4)
thiadiazolo(3,2-α)pyrimidine-6-carbonitrile derivatives. The in-vitro anticancer activities of these
compounds were evaluated against four human tumor cell lines. Among all the synthesized
derivatives, compound 4i, which has substituent 3-hydroxy-4-methoxyphenyl is found to have
the highest GI50 value of 32.7 µM, 55.3 µM, 34.3 µM, 28.9 µM for MCF-7, K562, HeLa and PC-3 cancer
cell lines respectively. A docking study of the newly synthesized compounds were performed, and
the results showed good binding mode in the active site of thymidylate synthase enzyme. ADME
properties of synthesized compounds were also studied and showed good drug like properties.
Keywords: 1,3,4-thiadiazolo(3,2-α)pyrimidine; ultrasound-promoted synthesis; ADME; docking
1. Introduction
Cancer is a disease in which cells grow and proliferate in an uncontrolled manner. Cancer
disease evokes a high level of mortality regardless of recent advances in the development of clinically
authorized anticancer agents [1]. On the basis of source and action mechanisms, the anticancer drugs
are classified as alkylating agents, antimetabolites, natural products, hormones and antagonistic,
miscellaneous agents. Many scientists are intensively engaged in the development of new anticancer
active agents that reveal a selective cytotoxicity for cancer cells over normal cells which is undoubtedly
needed to treat the severe cancer disease more efficiently and is also less toxic, since many of the
marketed anticancer drugs are toxic in nature [2–4].
Folate metabolism is considered as an important target for the development of new anticancer agents
due to its role in the biosynthesis of nucleic acid precursors [5,6]. The inhibition of folate dependent
enzymes such as thymidylate synthase (TS), which catalyzes the reductive methylation of deoxyuridylate
(dUMP) to thymidylate (dTMP) has also been recognized as an interesting target for drug discovery [7,8].
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Inhibition of this enzyme leads to thymineless state, rendering cells incapable of undergoing accurate
DNA replication, ultimately resulting in cell death. Classical, antifolate inhibitors of thymidylate synthase
often suffer from a number of potential disadvantages when used as anticancer agents. These include
impaired uptake due to an alteration of the active transport system required for cellular uptake, as well
as the formation of long acting, non-effluxing polyglutamates via folypolyglutamate synthetase, which
are responsible for toxicity to normal cells. Nonclassical antifolates such as nolatrexed (AG337), AG331,
pyrimethamine, trimethoprim (TMP), piritrexim (PTX) and trimetrexate (TMQ) do not require folate
transport systems but enter cells via passive diffusion. Recent advances in non-classical antifolates have
been documented in the literature [9–11]. To overcome some of the disadvantages of classical thymidylate
synthase inhibitors, our team has tried to synthesize novel 5-amino-2-(4-chlorophenyl)-7-substituted
phenyl-8,8a-dihydro-7H-(1,3,4)thiadiazolo(3,2-α)pyrimidine-6-carbonitrile derivatives.
Pyrimidine and its derivatives have been recognized as important heterocyclic compounds due to
their variety of chemical and biological significance to medicinal chemistry [12–15]. Hybridization of two
different bioactive molecules with complementary pharmacophoric functions often showed synergistic
effects [16,17]. During recent years, there have been intense investigations of fused thiadiazole and
pyrimidine systems. Literature survey revealed that (1,3,4)thiadiazolo(3,2-α)pyrimidine nucleus
is associated with diverse pharmacodynamic and chemotherapeutic activities [18,19], including
antimicrobial [19–21] and antitumor activities [18,20], herbicidal, antifungal, neuramidase inhibitors.
1,3,4-thiadiazolo(3,2-α)pyrimidines have been used as key building blocks for the preparation of a
variety of novel bioactive agents [22], therefore, we thought it worthwhile to explore this coupled
heterocyclic system for evaluation of anticancer activity. The designing protocol for a targeted
compound is as shown in Figure 1.
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Figure 1. Designing protocol for targeted molecule. 
The conventional multistep methods for the preparation of complex molecules involve large 
synthetic operations, including extraction and purification processes for each individual step, that 
lead to synthetic inefficiency and the generation of large amounts of waste. Therefore, designing 
multicomponent reactions (MCRs) in one pot and the creation of several bonds in a single operation 
are the major challenges for modern organic chemistry. 
The synthesis of heterocycles using toxic and hazardous chemicals which cause pollution has given 
birth to “Green Chemistry,” coined by Paul Anastas in 1998 [23]. Ultrasound-promoted synthesis is one 
of the green methods of synthesis which we have used in our present research work in order to prevent 
pollution. Ultrasound-promoted synthesis has various advantages over conventional synthetic 
techniques such as highly accelerated reaction rate, reasonably good yields, simple open systems, very 
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The conventional multistep methods for the preparation of complex molecules involve large
synth tic operations, including extraction and purification processes for ac individual step, that
lead to synthetic i efficiency and the generation of large amounts of waste. Therefore, designing
multicomponent reactions (MCRs) in one pot and the creation of several bonds in a single operation
are the major challenges for modern organic chemistry.
The synthesis of heterocycles using toxic and hazardous chemicals which cause pollution has
given birth to “Green Chemistry,” coined by Paul Anastas in 1998 [23]. Ultrasound-promoted synthesis
is one of the green methods of synthesis which we have used in our present research work in order to
prevent pollution. Ultrasound-promoted synthesis has various advantages over conventional synthetic
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techniques such as highly accelerated reaction rate, reasonably good yields, simple open systems, very
low amount of solvents required, eco friendly method, clean heating system, neat and clean synthetic
protocol, cheaper reagents and less extreme physical conditions, control on reaction parameters, milder
reaction conditions.
The existing synthetic methodologies for (1,3,4)thiadiazolo(3,2-α)pyrimidine nucleus in a modular
fashion are not straightforward and the synthetic routes involve multiple steps. For example,
1,3,4-thiadiazolo(3,2-α)pyrimidine-7-sulfonamide derivatives were synthesized from 5-aminol-3,4-
thiadiazole-2-sulfonamide via a two steps approach [24]. Salimov et al. [25] prepared 2-bromo-7-methyl-
5-oxo-5H-1,3,4-thiadiazolo(3,2-α)pyrimidine by two steps involving the addition of 2-aminothiadiazole
derivatives to ethyl acetoacetate, tandem hydrolysis of the ester to the acid, and cyclization to
give the ring-fused thiadiazolo(3,2-α)pyrimidines in PPA. Most of these are multistep protocols,
which suffer from generation of by-products, low yields, and use of metal-containing reagents.
Therefore, it is quite significant to develop the direct, efficient, and green alternative approaches to
get the functionalized thiadiazolo(3,2-α)pyrimidine derivatives from viewpoint of green chemistry.
Herein we reported a new, simple protocol for an environment friendly, rapid and convenient
synthesis, and antitumor activity against MCF-7, K562, HeLa, PC-3 cancer cell lines, of novel
5-amino-2-(4-chlorophenyl)-7-substituted phenyl-8,8a-dihydro-7H-(1,3,4)thiadiazolo(3,2-α)pyrimidine-
6-carbonitrile derivatives obtained in excellent yield through a one-pot three component condensation
reaction of 5-(4-chlorophenyl)-1,3,4-thiadiazol-2 amine, aromatic aldehyde and malononitrile using
sodium hydroxide as catalyst in ultrasound. Moreover, docking studies using thymidylate synthase
(TS) enzyme are presented in this paper as well.
2. Result and Discussion
2.1. Chemistry
Herein we report the one-pot synthesis of novel 5-amino-2-(4-chlorophenyl)-7-substituted
phenyl-8,8a-dihydro-7H-(1,3,4)thiadiazolo(3,2-α)pyrimidine-6-carbonitrile derivatives from three
component reactions of an 5-(4-chlorophenyl)-1,3,4-thiadiazol-2 amine (1), aromatic aldehydes (3) and
malononitrile (2) in presence of NaOH under reflux and ultrasonic irradiation as shown in Scheme 1.
To determine the optimal reaction conditions, the one pot reactions between 5-(4-chlorophenyl)-
1,3,4-thiadiazol-2 amine (1), suitable aldehyde (3), malononitrile (2) were carried out using different
solvents in the presence of NaOH as a catalyst at different mole percentage as shown in Table 1, the
desired product was not formed when H2O was chosen as solvent and instead acetonitrile, methanol
and dimethylformaide was chosen as solvent. The desired product was formed in low yield under
reflux and ultrasonic irradiation as shown in Table 1. The optimization of reaction conditions for
1,3,4-thiadiazolo(3,2-α)pyrimidine skeleton is as shown in Table 2. All the synthesized compounds
were characterized by 1H-NMR, 13C-NMR, mass spectroscopy and IR.
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Scheme 1. One-Pot, three component synthesis of novel 5-amino-2-(4-chlorophenyl)-7-substituted 
phenyl-8,8a-dihydro-7H-(1,3,4)thiadiazolo(3,2-α)pyrimidine-6-carbonitrile derivatives. Scheme 1. One-Pot, three component synthesis of novel 5-amino-2-(4-chlorophenyl)-7-substituted
phenyl-8,8a-dihydro-7H-(1,3,4)thiadiazolo(3,2-α)pyrimidine-6-carbonitrile derivatives.
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Table 1. Optimization of reaction conditions for novel 5-amino-2-(4-chlorophenyl)-7-substituted
phenyl-8,8a-dihydro-7H-(1,3,4)thiadiazolo(3,2-α)pyrimidine-6-carbonitrile derivatives using various
solvent and different mole percentage of NaOH.
Entry Catalyst Amount (% mol) Solvent
Method A Conventional Method B Ultrasound
Time (h) Yield (%) Time (h) Yield (%)
1 No catalyst - EtOH 9 - 2 -
2 NaOH 30 EtOH 9 70 2 89
3 NaOH 20 EtOH 9 70 2 89
4 NaOH 20 H2O 9 - 2 -
5 NaOH 20 MeOH 11 55 2.30 60
6 NaOH 20 CH3CN 11 40 2.30 50
7 NaOH 20 DMF 12 40 2.30 55
8 NaOH 10 EtOH 13 60 2.45 65
9 NaOH 5 EtOH 15 50 3.30 60
Table 2. Optimization of reaction conditions for 1,3,4-thiadiazolo(3,2-α)pyrimidine skeleton.
Compound R
Conventional Ultrasound
Time (h) Yield (%) Time (h) Yield (%)
4a 4-chlorophenyl 7 70 1 89
4b 2-chlorophenyl 7.30 68 1.30 85
4c 3-chlorophenyl 7.30 65 1.30 85
4d 4-flurophenyl 7 62 1.30 80
4e 4-methoxyphenyl 8 58 2 75
4f 3,4,5-methoxyphenyl 9 58 2 78
4g 3,4-methoxyphenyl 9 55 2 75
4h Phenyl 7 60 1 80
4i 3-hydroxy-4 methoxyphenyl 9 60 2 82
4j furan-2-yl 8 45 1.30 65
2.2. In Vitro Anticancer Activity
The target compounds (4a–j) were evaluated for their anticancer activity against MCF-7, K562,
HeLa and PC-3 cancer cell lines. The GI50 values (concentration required to Growth inhibition of 50%)
for the synthesized compounds were determined using SRB assays method. The anticancer evaluation
results and GI50 values were listed in Table 3 and the well-known anticancer drug 5-FU was used as
positive control.
Table 3. In-vitro anticancer activity.
Compound GI50 µM
MCF-7 K-562 HeLa PC-3
4a 88.5 47.9 56.2 38.9
4b 43.8 57.1 54.3 37.9
4c 55.0 60.1 55.7 38.4
4d 80.6 >100 58.1 30.2
4e 38.9 54.2 43.8 26.7
4f 38.3 58.1 48.6 25.4
4g 34.8 54.3 47.9 25.3
4h 38.9 58.3 38.7 34.7
4i 32.7 55.3 34.3 28.9
4j 82.5 >100 60.9 55.3
5-FU 32.18 47.03 43.71 12.00
5-Flurouracil (5-FU) was the standard drug used. GI50 is the concentration exhibiting 50% inhibition of the
growth as compared to the growth of control. MCF-7 Human breast cancer, K-562 Human Leukemia cancer,
HeLa Human cervical cancer, PC-3 Human prostate cancer.
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The results indicated that the compounds, 4e, 4f, 4g and 4i exhibited significant cell growth
inhibition compared to reference standard 5-fluorouracil against MCF-7, K562, HeLa and PC-3 cancer
cell lines. From the anticancer activity results, it was observed that compound 4i, which has substituent
3-hydroxy-4-methoxyphenyl, is found to have the highest GI50 values of 32.7 µM, 34.3 µM, 55.3 µM,
28.9 µM for MCF-7, HeLa, K562 and PC-3 cancer cell lines respectively. Compound 4g, which has
3,4-dimethoxyphenyl, is found to have GI50 values of 34.8 µM, 54.3 µM, 47.9 µM, 25.3 µM for MCF-7,
K562, HeLa, and PC-3 cancer cell lines respectively. All the synthesized compounds were less active
towards PC-3 in comparison to standard drug 5-FU.
Structural activity relationship (SAR) studies for these compounds demonstrated that electron
withdrawing groups such as fluoro (4d), chloro (4a, 4b, 4c) exhibited less activity compared to electron
donating, polar groups. The anticancer activity for derivatives bearing an electron withdrawing group
such as chloro group at ortho position (4b) (43.8 µM, 57.1 µM, 54.3 µM, 37.9 µM for MCF-7, K-562,
HeLa and PC-3 cancer cell lines respectively) exhibited more activity than compound 4c (chloro group
at meta position) (55.0 µM, 60.1 µM, 55.7 µM, 38.4 µM for MCF-7, K-562, HeLa and PC-3 cancer cell
lines respectively) and compound 4a (chloro group at para position) (88.5 µM, 47.9 µM, 56.2 µM,
38.9 µM for MCF-7, K-562, HeLa and PC-3 cancer cell lines respectively). Replacement of the phenyl
group in the parent compound by furan ring in 4j has shown decreased activity in comparison to the
standard drug 5-FU (82.5 µM, >100 µM, 60.9 µM, 55.30 µM, for MCF-7, K-562, HeLa and PC-3 cancer
cell lines, respectively). From SAR it can be considered that compounds containing electron donating,
polar groups such as 4e, 4f, 4g, 4i have good anticancer activity in comparison to electron withdrawing
groups such as 4a, 4b, 4c, 4d. It is also clear that the replacement of the phenyl ring with the furan ring
decreases anticancer activity.
4i and 4g are equipotent with the clinically used anticancer drug 5-FU against MCF-7, HeLa cell
lines, hence these compounds can be developed as anticancer agents in the future. Compound 4a is
equipotent with the clinically used anticancer drug 5-FU against K-562.
2.3. Molecular Docking
5-Fluorouracil derivatives and their structurally related compounds like pemetrexed, Capecitibine,
Raltitrexed are well known to inhibit thymidylate synthase. We decided to carry out a molecular
docking study on our newly synthesized 1,3,4-thiadiazolo(3,2-α)pyrimidine skeleton derivatives into
the binding site of thymidylate synthase (PDB ID: 1JU6) using 5-FU as a reference for docking results.
The docking results indicated that compounds were held in the active pocket by combination of various
hydrogen and hydrophobic interactions with TS. The docking results revealed that the highest binding
compound to TS was 4i with a G-Score of ´7.17. The compound 4g shows hydrogen bonding with
ASN 112, ILE 108 and ARG 50 with a G-Score of ´5.59 as shown in Figure 2. Similarly, the compound
4i shows hydrogen bonding with GLN 214, SER 214 and ASN 226 with a highest G-Score of ´7.17 as
shown in Figure 3. The compounds 4b (´5.59), 4c (´5.24), 4d (´5.14), 4f (´5.14), 4h (´5.38) and
4j (´4.98), all showed G-Score greater than 5-FU (´4.75).
On the basis of the anticancer activity and docking results, it was found that compounds 4g, 4h
and 4i had potential to inhibit thymidylate synthase. G-Score of all the synthesized derivatives is as
shown in Table 4.
Table 4. G-Score of all the synthesized derivatives.
Compound G-Score Compound G-Score
4a ´4.65 4g ´5.59
4b ´5.59 4h ´5.38
4c ´5.24 4i ´7.17
4d ´5.14 4j ´4.98
4e ´4.74 5-FU ´4.75
4f ´5.14
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2.4. In Silico ADME Prediction
The prediction of the ADME parameters prior to the experimental studies is one of the most
important aspects of drug discovery and development of the drug molecule. ADME studies have
always played a critical role in helping to optimize the pharmacokinetic properties of new drugs,
thereby increasing their success rate. The analysis of Lipinski’s rule of five was performed to indicate
whether a chemical compound could be an orally active drug in humans. It was observed that the
compounds exhibited a good % absorption (% ABS) ranging from 87.50% to 100% (Table 5).
The results of the prediction of ADME properties are depicted in Table 5. All synthesized
compounds 4a–j had good absorption and were found to be nontoxic.
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(–2.0 to 6.5) n-ON





Rule of 5 (<5)
Toxicity
4a 400 100 4.57 4 2 74.81 0 N
4b 400 100 4.42 4 2 74.87 0 N
4c 400 100 4.57 4 2 74.81 0 N
4d 383.8 100 4.30 4 2 74.81 0 N
4e 395.8 100 4.19 4.75 2 83.10 0 N
4f 455.9 100 4.47 6.25 2 95.95 0 N
4g 425.8 100 4.36 5.5 2 88.02 0 N
4h 365.8 100 4.01 4 2 74.81 0 N
4i 411.8 87.50 3.46 5.5 3 104.7 0 N
4j 355.8 94.19 3.12 4.5 2 83.51 0 N
5-FU 130.0 66.30 ´0.89 3.5 2 87.56 0 N
a Molecular weight of the molecule; b Percentage human oral absorption (% ABS) (>80% is high, <25% is poor); c Predicted octanol-water partition coefficient (logP o/w) (–2.0 to 6.5);
d n-ON number of hydrogen bond acceptors <10; e n-OHNH number of hydrogen bonds donors <5; f Polar surface area (PSA) (7.0–200.0); N: non-toxic.
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3. Materials and Methods
3.1. General
All the reactions were performed in oven-dried glasswares. All reagents and solvents were used
as obtained from the supplier or recrystallized/redistilled unless otherwise noted. The ultrasound
sonicator (Sonics Vibra-cell, Modelno. VCX 500, Newtown, CT, USA) equipped with solid synthetic
probe, 13 mm in tip diameter, operating at 20 kHz with a maximum power output of 500 W, was
used for synthesis of final title compounds. The purity of the synthesized compounds was monitored
by ascending thin layer chromatography (TLC) on silica gel-G (Merck, Darmstadt, Germany) coated
aluminum plates, visualized by iodine vapor and melting points were determined in open capillary
tubes. Infrared (IR) spectra were recorded on a PS 4000 FTIR (JASCO, Tokyo, Japan) using KBr pellets.
Elemental analyses (C, H, and N) were done with a FLASHEA 112 Shimadzu’ analyzer (Mumbai,
Maharashtra, India) and all analyses were consistent (within 0.4%) with theoretical values. The
1H-NMR and 13C-NMR spectra of synthesized compounds were recorded on Bruker Avance II 400
NMR Spectrometer (Billerica, MA, USA) at 400 MHz Frequency in deuterated DMSO and CDCl3 and
using TMS as internal standard (chemical shift δ in ppm). Mass spectra of some compounds were
scanned on FTMS + p ESI full mass (100.00–1500.00).
3.2. General Procedure for the Synthesis of 5-Amino-2-(4-chlorophenyl)-7-Substituted
Phenyl-8,8a-dihydro-7H-(1,3,4)thiadiazolo(3,2-α)pyrimidine-6-carbonitrile Derivatives
Method A: A 25 mL round bottom flask was charged with a mixture of an 5-(4-chlorophenyl)-
1,3,4-thiadiazol-2 amine (0.01 mol) (1), malononitrile (0.01 mol) (2), suitable aldehyde (0.01 mol) (3)
in ethanol (10–12 mL) and the catalyst NaOH (20% mmol) and the reaction mixture was refluxed .
After completion of the reaction (monitored by TLC), the mixture was poured into ice cold water. The
product obtained, was filtered and dried. The corresponding product was obtained in high purity after
recrystallization of the crude product from ethanol. The authenticity of compounds was established by
1H-NMR, 13C-NMR, IR and HRMS.
Method B: A 25 mL a beaker was charged with a mixture of an 5-(4-chlorophenyl)-1,3,4-
thiadiazol-2 amine (0.01 mol) (1), malononitrile (0.01 mol) (2), suitable aldehyde (0.01 mol) (3) in
ethanol (10–12 mL) and the catalyst NaOH (20% mmol) and the reaction mixture was kept inside
an Ultrasonicator acoustic chamber at 80 ˝C at 20%. After completion of the reaction (monitored by
TLC), the mixture was poured into ice cold water. The product obtained, was filtered and dried. The
corresponding product was obtained in high purity after recrystallization of the crude product from
ethanol. The authenticity of compounds was established by 1H-NMR, 13C-NMR, IR and HRMS.
5-Amino-2,7-bis(4-chlorophenyl)-7H-(1,3,4)thiadiazolo(3,2-α)pyrimidine-6-carbonitrile 4a. M.P: 237–240 ˝C.
Rf value: 0.28. IR (KBr) υmax cm´1: 3400 (C-NH2), 3100 (Aromatic C-H stretching), 1623 (C=N), 740.55
(C-Cl of aromatic rings), 1H-NMR δ ppm: 10.00 (s, 2H, NH2), 8.00–7.02 (m, 8H two aromatic rings), 3.35
(s, 1H, ArC, of pyrimidine ring), 13C-NMR δ: 172.11 (C), 158.31 (C), 143.21 (C), 139.50 (C), 136.51 (C),
131.00 (C), 130.52 (CH), 129.87 (CH), 128.53 (CH), 128.23 (C), 127.93 (CH), 118.27 (C), 60.22 (C), 54.53
(C), m/z 399 (100.0%), 401.01 (68.9%), 400.01 (22.7%) Molecular Formula: C18H11Cl2N5S. Elemental
Analysis: Calculated: (C, H, Cl, N, S) 54.01, 2.77, 17.71, 17.50, 8.01 Found: 55.04, 2.74, 17.68, 17.51, 8.00.
5-Amino-7-(2-chlorophenyl)-2-(4-chlorophenyl)7H-(1,3,4)thiadiazolo(3,2-α)pyrimidine-6-carbonitrile 4b. M.P:
240–242 ˝C. Rf value: 0.24. IR (KBr) υmax cm´1: 3400 (C-NH2), 3000 (Aromatic C-H stretching), 1623
(C=N), 740.55 (C-Cl of aromatic rings). 1H-NMR δ ppm: 9.98 (s, 2H, NH2), 8.00–7.09 (m, 8H two
aromatic rings), 3.35 (s, 1H, ArC, of pyrimidine ring), 13C-NMR δ ppm: 170.24 (C), 158.37 (C), 143.77
(C), 138.10 (C), 134.26 (C), 129.52 (CH), 129.00 (CH), 128.51 (CH), 128.03 (C), 127.99 (CH), 126.11 (CH),
117.59 (C), 60.00 (C), 55.02 (C), m/z 399 (100.0%), 401.01 (68.9%), 400.01 (22.7%) Molecular Formula:
C18H11Cl2N5S. Elemental Analysis: Calculated: (C, H, Cl, N, S) 54.01, 2.77, 17.71, 17.50, 8.01 Found:
55.02, 2.76, 17.70, 17.52, 8.02.
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5-Amino-7-(3-chlorophenyl)-2-(4-chlorophenyl)7H-(1,3,4)thiadiazolo(3,2-α)pyrimidine-6-carbonitrile 4c. M.P:
235–238 ˝C. Rf value: 0.20. IR (KBr) υmax cm´1: 3400 (C-NH2), 3100 (Aromatic C-H stretching), 162.3
(C=N), 740.55 (C-Cl of aromatic rings), 1H-NMR δ ppm: 10.01 (s, 2H, NH2), 8.00–7.05 (m, 8H two
aromatic rings), 3.32 (s, 1H, ArC, of pyrimidine ring), 13C-NMR δ ppm: 172.21 (C), 158.20 (C), 155.00
(C), 142.50 (C), 137.69 (C), 136.17 (C), 134.09 (C), 130.03 (CH), 129.99 (CH), 129.02 (CH), 128.93 (CH),
128.37 (CH), 125.59 (CH), 123.95 (CH), 119.11 (CH), 117.57 (C), 59.97 (C), 52.00 (C), m/z 399 (100.0%),
401.01 (68.9%), 400.01 (22.7%), Molecular Formula: C18H11Cl2N5S. Elemental Analysis: Calculated:
(C, H, Cl, N, S) 54.01, 2.77, 17.71, 17.50, 8.01 Found: 55.01, 2.77, 17.67, 17.49, 8.03.
5-Amino-2-(4-chlorophenyl)-7-(4-fluorophenyl)-7H-(1,3,4)thiadiazolo(3,2-α)pyrimidine-6-carbonitrile 4d. M.P:
239–240 ˝C. Rf value: 0.37. IR (KBr) υmax cm´1: 3400 (C-NH2), 3000 (Aromatic C-H stretching), 1623
(C=N), 740.55 (C-Cl of aromatic ring), 1053 (C-F of aromatic rings), 1H-NMR δ ppm: 9.79 (s, 2H, NH2),
8.02–7.06 (m, 8H two aromatic rings), 3.33 (s, 1H, ArC, of pyrimidine ring), 13C-NMR δ ppm: 172.22
(C), 159.07 (C), 158.31 (C), 143.77 (C), 136.62 (C), 136.99 (C), 130.67 (CH), 129.52 (CH), 128.99 (C), 128.77
(CH), 117.54 (C), 115.34 (CH), 60.07 (C), 52.97 (C), m/z 383.04 (100%), 385.04 (37%), 384.04 (22.7%),
Molecular Formula: C18H11ClFN5S. Elemental Analysis: Calculated: (C, H, Cl, F, N, S) 56.33, 2.89, 9.24,
4.95, 18.25, 8.35 Found: 56.37, 2.90, 9.20, 4.91, 18.23, 8.36.
5-Amino-2-(4-chlorophenyl)-7-(4-methoxyphenyl)-7H-(1,3,4)thiadiazolo(3,2-α)pyrimidine-6-carbonitrile 4e.
M.P: 210–212 ˝C. Rf value: 0.36. IR (KBr) υmax cm´1: 3400 (C-NH2); 3000 (Aromatic C-H stretching),
1623 (C=N), 1055 (C-OCH3), 740.55 (C-Cl of aromatic ring), 1H-NMR δ ppm: 9.99 (s, 2H, NH2), 8.02–6.79
(m, 8H two aromatic rings), 3.36 (s, 1H, ArC, of pyrimidine ring), 3.56 (s, 3H, OCH3), 13C-NMR δ ppm:
172.26 (C), 158.99 (C), 157.51 (C), 143.70 (C), 136.99 (C), 133.04 (C), 130.07 (CH), 129.55 (CH), 128.52
(CH), 128.00 (C), 117.37 (C), 114.26 (CH), 60.00 (C), 55.99 (CH3), 53.00 (C), m/z 395.06 (100%), 397.06
(37.0%), 396.06 (23.8%), Molecular Formula: C19H14ClN5OS. Elemental Analysis: Calculated: (C, H, Cl,
N, O, S) 57.65, 3.56, 8.96, 17.69, 4.04, 8.10 Found: 57.68, 3.59, 8.93, 17.67, 4.03, 8.11.
5-Amino-2-(4-chlorophenyl)-7-(3,4,5-trimethoxyphenyl)-7H-(1,3,4)thiadiazolo(3,2-α)pyrimidine-6-carbonitrile
4f. M.P: 220–222 ˝C. Rf value: 0.26. IR (KBr) υmax cm´1: 3400 (C-NH2), 3100 (Aromatic C-H
stretching), 1623 (C=N), 1059 (C-OCH3), 740.55 (C-Cl of aromatic ring), 1H-NMR δ ppm: 10.00 (s, 2H,
NH2), 8.02–6.79 (m, 6H two aromatic rings), 3.36 (s, 1H, ArC, of pyrimidine ring), 3.56 (s, 9H, OCH3),
13C-NMR δ ppm: 172.21 (C), 158.89 (C), 152.81 (C), 143.32 (C), 136.52 (C), 136.00 (C), 135.01 (C), 129.51
(CH), 128.52 (CH), 128.77 (C), 117.51 (C), 106.50 (CH), 61.00 (CH3), 60.52 (C), 56.00 (CH3), 53.00 (C),
m/z 455.08 (100%), 457.08 (37.1%), 456.09 (23.7%), Molecular Formula: C21H18ClN5O3S. Elemental
Analysis: Calculated: (C, H, Cl, N, O, S) 55.32, 3.98, 7.78, 15.36, 10.53, 7.03 Found: 55.37, 3.99, 7.77,
15.33, 10.52, 7.00.
5-Amino-2-(4-chlorophenyl)-7-(3,4-dimethoxyphenyl)-7H-(1,3,4)thiadiazolo(3,2-α)pyrimidine-6-carbonitrile 4g.
M.P: 225–228 ˝C. Rf value: 0.50. IR (KBr) υmax cm´1: 3400 (C-NH2), 3100 (Aromatic C-H stretching),
1623 (C=N), 1623 (C=N), 1052 (C-OCH3), 740.55 (C-Cl of aromatic ring), 1H-NMR δ ppm: 10.02 (s, 2H,
NH2), 8.02–6.79 (m, 7H two aromatic rings), 3.36 (s, 1H, ArC, of pyrimidine ring), 3.56 (s, 6H, OCH3),
13C-NMR δ ppm: 172.07 (C), 158.00 (C), 149.07 (C), 146.72 (C), 143.54 (C), 136.58 (C), 134.51 (C), 129.59
(CH), 128.55 (CH), 128.70 (C), 122.01 (C), 117.56 (C), 114.99 (CH), 112.53 (CH), 59.11 (C), 56.09 (CH3),
53.00 (C), m/z 425.07 (100.0%), 427.07 (37.0%), 426.07 (24.09%), Molecular Formula: C20H16ClN5O2S.
Elemental Analysis: Calculated: (C, H, Cl, N, O, S) 56.40, 3.79, 8.32, 16.44, 7.51, 7.53 Found: 56.44, 3.82,
8.30, 16.00, 7.50, 7.52.
5-Amino-2-(4-chlorophenyl)-7-phenyl-7H-(1,3,4)thiadiazolo(3,2-α)pyrimidine-6-carbonitrile4h. M.P: 218–220 ˝C.
Rf value: 0.43. IR (KBr) υmax cm´1: 3400 (C-NH2), 3000 (Aromatic C-H stretching), 1623 (C=N), 740.55
(C-Cl of aromatic ring), 1H-NMR δ ppm: 10.00 (s, 2H, NH2), 8.02–7.27 (m, 9H two aromatic rings),
3.34 (s, 1H, ArC, of pyrimidine ring), 13C-NMR δ ppm: 172.12 (C), 158.37 (C), 143.77 (C), 141.00 (C),
136.50 (C), 129.55 (CH), 129.08 (CH), 128.61 (C), 128.52 (CH), 125.79 (CH), 125.60 (CH), 117.51 (C), 60.00
(C), 53.12 (C), m/z 365.05 (100.0%), 367.05 (37.0%), 366.05 (22.7%), Molecular Formula: C18H12ClN5S.
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Elemental Analysis: Calculated: (C, H, Cl, N, S) 59.09, 3.31, 9.69, 19.14, 8.76 Found: 59.13, 3.33, 9.67,
19.10, 8.75.
5-Amino-2-(4-chlorophenyl)-7-(3-hydroxy-4-methoxyphenyl)-7H-(1,3,4)thiadiazolo(3,2-α)pyrimidine-6-carbonitrile
4i. M.P: 240–245 ˝C. Rf value: 0.51. IR (KBr) υmax cm´1: 3400 (C-NH2), (C-OH) 3333, 3000 (Aromatic
C-H stretching), 1623 (C=N), 1055 (C-OCH3), 740.55 (C-Cl of aromatic ring), 1H-NMR δ ppm: 10.00 (s,
2H, NH2), 8.00–6.57 (m, 9H two aromatic rings), 5.35 (s, 1H, OH), 3.56 (s, 3H, OCH3), 3.34 (s, 1H, ArC, of
pyrimidine ring), 13C-NMR δ ppm: 172.11 (C), 158.29 (C), 147.17 (C), 147.00 (C), 143.77 (C), 136.69 (C),
134.91 (C), 129.54 (CH), 128.69 (CH), 128.56 (C), 122.63 (CH), 117.58 (C), 115.07 (CH), 112.62 (CH),
60.00 (C), 56.02 (CH3), 53.07 (C), m/z 411.06 (100.0%), 413.05 (36.4%), 412.06 (22.2%), Molecular
Formula: C19H14ClN5O2S. Elemental Analysis: Calculated: (C, H, Cl, N, O, S) 55.41, 3.43, 8.61, 17.00,
7.77, 7.79 Found: 55.44, 3.44, 8.59, 17.00, 7.79, 7.80.
5-Amino-2-(4-chlorophenyl)-7-(furan-2-yl)-7H-(1,3,4)thiadiazolo(3,2-α)pyrimidine-6-carbonitrile 4j. M.P:
200–210 ˝C. Rf value: 0.49. IR (KBr) υmax cm´1: (C-NH2), 3000 (Aromatic C-H stretching), 1623 (C=N),
740.55 (C-Cl of aromatic ring), 1H-NMR δ ppm: 9.08 (s, 2H, NH2), 7.77–7.55 (m, 4H two aromatic
rings), 7.52 d, 1H, furan ring), 6.40 (t, 1H, furan ring), 6.08 (d, 1H, furan ring), 3.71 (s, 1H, ArC, of
pyrimidine ring), 13C-NMR δ ppm: 172.17 (C), 157.77 (C), 152.59 (C), 144.32 (C), 142.36 (CH), 136.71 (C),
129.75 (CH), 129.00 (CH), 128.70 (C), 117.29 (C), 111.00 (CH), 105.97 (CH), 59.60 (C), 54.37 (C), m/z
355.03 (100%), 357.03 (37.1%), 356.03 (20.5%), Molecular Formula: C16H10ClN5OS. Elemental Analysis:
Calculated: (C, H, Cl, N, O, S) 54.01, 2.83, 9.96, 19.68, 4.56, 9.01 Found: 54.05, 2.85, 9.95, 19.67, 4.56, 9.00.
3.3. Anticancer Screening
Experimental procedure for SRB assay [26].
The cell lines were grown in RPMI 1640 medium containing 10% fetal bovine serum and 2 mM
L-glutamine. For the present screening experiment, cells were inoculated into 96 well microtiter
plates in 90 µL at 5000 cells per well. After cell inoculation, the microtiter plates were incubated at
37 ˝C, 5% CO2, 95% air and 100% relative humidity for 24 h prior to addition of experimental drugs.
Experimental drugs were solubilized in an appropriate solvent to prepare stock of 10´2 concentration.
At the time of experiment, four 10-fold serial dilutions were made using complete medium. Aliquots
of 10 µL of these different drug dilutions were added to the appropriate micro-titer wells already
containing 90 µL of medium, resulting in the required final drug concentrations.
After compound addition, plates were incubated at standard conditions for 48 h and the assay
was terminated by the addition of cold TCA. Cells were fixed in situ by the gentle addition of 50 µL of
cold 30% (w/v) TCA (final concentration, 10% TCA) and incubated for 60 min at 4 ˝C. The supernatant
was discarded; the plates were washed five times with tap water and air dried. Sulforhodamine B
(SRB) solution (50 µL) at 0.4% (w/v) in 1% acetic acid was added to each of the wells, and plates
were incubated for 20 min at room temperature. After staining, unbound dye was recovered and the
residual dye was removed by washing five times with 1% acetic acid. The plates were air dried. Bound
stain was subsequently eluted with 10 mM trizma base, and the absorbance was read on an Elisa plate
reader at a wavelength of 540 nm with 690 nm reference wavelength.
Percent growth was calculated on a plate-by-plate basis for test wells relative to control wells.
Percent Growth was expressed as the ratio of average absorbance of the test well to the average
absorbance of the control wells ˆ 100. Using the six absorbance measurements (time zero (Tz),
control growth (C), and test growth in the presence of drug in the four concentration levels (Ti)),
the percentage growth was calculated at each of the drug concentration levels. The dose response
parameters were calculated for each test article. Growth inhibition of 50% (GI50) was calculated from
((Ti ´ Tz)/(C ´ Tz)) ˆ 100 = 50, which is the drug concentration resulting in a 50% reduction in the
net protein increase (as measured by SRB staining) in control cells during the drug incubation. The
drug concentration resulting in total growth inhibition (TGI) was calculated from Ti = Tz.
Molecules 2016, 21, 894 11 of 13
Values were calculated for each of these three parameters if the level of activity was reached;
however, if the effect was not reached or was exceeded, the values for that parameter were expressed
as greater or less than the maximum or minimum concentration tested.
3.4. Molecular Docking
Molecular Docking Studies were performed in Maestro 9.1 using Glide v6.8 (Schrodinger, LLC,
New York, NY, USA). All compounds were built using Maestro build panel and optimized to lower
energy conformers using Ligprep v3.5.9 (Schrodinger, LLC) The coordinates for thymidylate synthase
enzyme were taken from RCSB Protein Data Bank and prepared for docking using ‘protein preparation
wizard’ in Maestro v10.3. (Schrodinger, LLC) The bond orders and formal charges were added for
heterogroups and hydrogens were added to all atoms in the structure. Side chains that are not close to
the binding cavity and do not participate in salt bridges were neutralized and termini were capped by
adding ACE and NMA residue. After preparation, the structure was refined to optimize the hydrogen
bond network using OPLS_2005 force field. The minimization was terminated when the energy
converged or the RMSD reached a maximum cutoff of 0.30 Å. The extra precision (XP) docking mode
for all compounds was performed on generated grid of protein structure [27–31]. The final evaluation
of ligand-protein binding was done with Glide score.
3.5. In Silico ADME Prediction
A computational study of synthesized compounds 4a–j was performed for prediction of ADME
properties. The absorption, distribution, metabolism and excretion (ADME) properties of all
compounds were predicted using Qikprop v3.5 (Schrödinger LLC). In the present study, we have
calculated the molecular volume (MV), molecular weight (MW), Predicted octanol-water partition
coefficient (log Po/w), number of hydrogen bond acceptors (n-ON), number of hydrogen bonds
donors (n-OHNH), Percentage human oral absorption (% ABS), Polar surface area (PSA). The above
described properties help us in understanding the ADME properties of any drug/synthesized molecule.
A molecule likely to be developed as an orally active drug candidate should show no more than one
violation of the following four criteria: log Po/w (octanol-water partition coefficient) ď 5, molecular
weightď 500, number of hydrogen bond acceptorsď 10 and number of hydrogen bond donorsď 5 [32].
4. Conclusions
The present work reports green synthetic route leading to the formation of antitumor
active 5-amino-2-(4-chlorophenyl)-7-substituted phenyl-8,8a-dihydro-7H-(1,3,4)thiadiazolo(3,2-α)
pyrimidine-6-carbonitrile and gives an impression about a clue for the mode of action by performing
molecular docking study. The present protocol is also extendable to a wide variety of substrates. The
advantages of this protocol are the use of eco-friendly catalyst, short reaction time, easy work-up, ease
of product isolation, and high yield. From the results of anticancer activity and docking study,
it is observed that the 1,3,4-thiadiazolo(3,2-α)pyrimidine skeleton is essential for the anticancer
activity. Compounds containing electron donating, polar groups such as 4e, 4f, 4g, 4i have good
anticancer activity in comparison to electron withdrawing groups. Among all the synthesized
derivatives, 4g and 4i were equipotent to standard drug 5-FU. Compound 4i, which has substituent
3-hydroxy-4-methoxyphenyl, is found to have the highest GI50 value of 32.7 µM, 55.3 µM, 34.3 µM,
28.9 µM for MCF-7, K562, HeLa and PC-3 cancer cell lines respectively. Compound 4g, which
has 3,4-dimethoxyphenyl, is found to have GI50 values of 34.8 µM, 54.3 µM, 38.7 µM, 34.7 µM for
MCF-7, K562, HeLa and PC-3 cancer cell lines respectively. Finally, the ADME study shows that the
synthesized drugs showed good drug like properties and opens the gateway for further optimization
of studied compounds.
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